NYSE:NVTAInVitae Stock Price, Forecast & News

InVitae's stock was trading at $15.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVTA stock has increased by 107.0% and is now trading at $32.81. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InVitae.

InVitae is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for InVitae.

InVitae Corp (NYSE:NVTA) announced its earnings results on Tuesday, May, 5th. The medical research company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.84) by $0.04. The medical research company earned $64.25 million during the quarter, compared to analysts' expectations of $59.41 million. InVitae had a negative net margin of 127.42% and a negative return on equity of 69.95%. The business's quarterly revenue was up 58.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.47) EPS. View InVitae's earnings history.

5 brokerages have issued 12-month price targets for InVitae's stock. Their forecasts range from $20.00 to $35.00. On average, they expect InVitae's stock price to reach $28.20 in the next twelve months. This suggests that the stock has a possible downside of 14.1%. View analysts' price targets for InVitae.

Press coverage about NVTA stock has trended very negative on Monday, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. InVitae earned a news impact score of -3.2 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about InVitae.

Some companies that are related to InVitae include Quest Diagnostics (DGX), Guardant Health (GH), Natera (NTRA), ELEKTA AB/ADR (EKTAY), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Fulgent Genetics (FLGT), Progenity (PROG), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ) and Biocept (BIOC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Roku (ROKU), Alibaba Group (BABA), Square (SQ), Trade Desk (TTD), Shopify (SHOP), Walt Disney (DIS), salesforce.com (CRM), Twilio (TWLO) and Micron Technology (MU).

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

InVitae's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.01%). Company insiders that own InVitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View institutional ownership trends for InVitae.

NVTA stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for InVitae.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVTA stock can currently be purchased for approximately $32.81.

InVitae has a market capitalization of $4.10 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe.

The official website for InVitae is www.invitae.com.

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]